ASCO 2024 – Scemblix could set new standard in front-line leukaemia
But will the FDA accept the surrogate endpoint used in ASC4First?
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
Novartis lights up radiopharmaceuticals again
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
